A novel approach for treating hepatocellular carcinoma: epigenetic therapy
-
摘要: 最近,研究显示肝细胞癌(HCC)的病理生理过程涉及DNA甲基化、组蛋白修饰、microRNA等表观遗传的改变。介绍了HCC表观遗传机制的一般特征以及HCC的表观遗传治疗进展。认为表观遗传治疗在HCC治疗中具有很好的应用前景,但距离临床应用还有很长的一段路要走。Abstract: Recent studies have shown that the pathophysiology of hepatocellular carcinoma( HCC) involves epigenetic alterations in DNA methylation,histone modifications,and microRNAs. In this review,we describe the general characteristics of epigenetic machinery in HCC as well as the current advances in epigenetic therapy for HCC. It is pointed out that epigenetic therapy has good prospects in the treatment of HCC,but there is still a long way before clinical application.
-
[1]LAFARO KJ,DEMIRJIAN AN,PAWLIK TM.Epidemiology of hepatocellular carcinoma[J].Surg Oncol Clin N Am,2015,24(1):1-17. [2]LIU HC.Interpretation of guidelines for the treatment of primary liver cancer in China[J].J Hepatobiliary Surg,2013,21(1):12-14.(in Chinese)刘会春.中国原发性肝癌治疗指南解读[J].肝胆外科杂志,2013,21(1):12-14. [3]FOMER A,DIAZ-GONZALEZ A,LICCIONI A,et al.Prognosis prediction and staging[J].Best Pract Res Clin Gastroenterol,2014,28(5):855-865. [4]MA L,CHUA MS,ANDRISANI O,et al.Epigenetics in hepatocellular carcinoma:an update and future therapy perspectives[J].World J Gastroenterol,2014,20(2):333-345. [5]MANDAVIVA PR,STOLK L,HEIL SG.Homocysteine and DNA methylation:a review of animal and human literature[J].Mol Genet Metab,2014,113(4):243-252. [6]LUJAMBIO A,ESTELLER M.Cp G island hypermethylation of tumor suppressor microRNAs in human cancer[J].Cell Cycle,2007,6(12):1455-1459. [7]FONG CY,MORISON J,DAWSON MA.Epigenetics in the hematologic malignancies[J].Haematologica,2014,99(12):1772-1783. [8]ANESTOPOULOS I,VOULGARIDOU GP,GEORGAKILAS AG,et al.Epigenetic therapy as a novel approach in hepatocellular carcinoma[J].Pharmacol Ther,2015,145:103-119. [9]POGRIBNY IP,RUSYN I.Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma[J].Cancer Lett,2014,342(2):223-230. [10]CHEN QW,ZHU XY,LI YY,et al.Epigenetic regulation and cancer(review)[J].Oncol Rep,2014,31(2):523-532. [11]YAO JY,ZHANG L,ZHANG X,et al.H3K27 trimethylation is an early epigenetic event of p16INK4a silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells[J].J Biol Chem,2010,285(24):18828-18837. [12]YU YL,SU KJ,HSIEH YH,et al.Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma[J].PLo S One,2013,8(9):e74870. [13]YUAN H,LI AJ,MA SL,et al.Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells[J].World J Gastroenterol,2014,20(17):4953-4962. [14]TURATO C,SIMONATO D,QUARTA S,et al.MicroRNAs and Serpin B3 in hepatocellular carcinoma[J].Life Sci,2014,100(1):9-17. [15] POGRIBNY IP,RUSYN I.Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma[J].Cancer Lett,2014,342(2):223-230. [16]MLLER AM,FLOREK M.5-Azacytidine/5-Azacitidine[J].Recent Results Cancer Res,2014,201:299-324. [17]VALDESPINO-GOMEZ VM,VALDESPINO-CASTILLO VE.Targeted epigenetic therapy of cancer.Achievements and perspectives[J].Cir Cir,2012,80(5):470-480. [18]BYUN HM,CHOI SH,LAIRD PW,et al.2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine:a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1[J].Cancer Lett,2008,266(2):238-248. [19]GNYSZKA A,JASTRZEBSKI Z,FLIS S.DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer[J].Anticancer Res,2013,33(8):2989-2996. [20]CORADINI D,SPERANZA A.Histone deacetylase inhibitors for treatment of hepatocellular carcinoma[J].Acta Pharmacol Sin,2005,26(9):1025-1033. [21]ZHANG J,ZHONG Q.Histone deacetylase inhibitors and cell death[J].Cell Mol Life Sci,2014,71(20):3885-3901. [22]WANG HG,HUANG XD,SHEN P,et al.Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro[J].Int J Mol Med,2013,31(4):967-974. [23]DE CONTI A,TRYNDYAK V,KOTURBASH I,et al.The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway[J].Carcinogenesis,2013,34(8):1900-1906. [24]WEST AC,JOHNSTONE RW.New and emerging HDAC inhibitors for cancer treatment[J].J Clin Invest,2014,124(1):30-39. [25]YEO W,CHUNG HC,CHAN SL,et al.Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma:a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group[J].J Clin Oncol,2012,30(27):3361-3367. [26] PARK JK,KOGURE T,NUOVO GJ,et al.miR-221 silencing blocks hepatocellular carcinoma and promotes survival[J].Cancer Res,2011,71(24):7608-7616. [27]CALLEGARI E,ELAMIN BK,GIANNONE F,et al.Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model[J].Hepatology,2012,56(3):1025-1033. [28]MENG XZ,ZHENG TS,CHEN X,et al.MicroRNA expression alteration after arsenic trioxide treatment in Hep G-2 cells[J].J Gastroenterol Hepatol,2011,26(1):186-193. [29]NAKAO K,MIYAAKI H,ICHIKAWA T.Antitumor function of microRNA-122 against hepatocellular carcinoma[J].J Gastroenterol,2014,49(4):589-593. [30]GREENHILL C.Hepatocellular carcinoma:new insight into angiogenesis in hepatocellular carcinoma:involvement of microRNA-26a[J].Nat Rev Gastroenterol Hepatol,2014,11(1):3. [31]LU Y,YUE X,CUI Y,et al.MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3[J].Biochem Biophys Res Commun,2013,441(4):873-879. [32]RAGGI C,FACTOR VM,SEO D,et al.Epigenetic reprogramming modulates malignant properties of human liver cancer[J].Hepatology,2014,59(6):2251-2262. [33]HSU FT,LIU YC,CHIANG IT,et al.Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-kappa B signaling[J].Int J Oncol,2014,45(1):177-188. [34]LU YS,CHOU CH,TZEN KY,et al.Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys,2012,83(2):e181-e189.
本文二维码
计量
- 文章访问数: 298
- HTML全文浏览量: 19
- PDF下载量: 255
- 被引次数: 0